Decreased Serum Retinoic Acid May Predict Poor Outcome in Ischemic Stroke Patients
Authors Xu M, Xu L, Du H, Shan W, Feng J, Zhai G, Yang X
Received 19 March 2020
Accepted for publication 16 May 2020
Published 10 June 2020 Volume 2020:16 Pages 1483—1491
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Jun Chen
Mengshi Xu,1,* Liang Xu,2,* Huaping Du,1 Wanying Shan,1 Jie Feng,1 Guojie Zhai,1 Xiuyan Yang1
1Department of Neurology, Suzhou Ninth People’s Hospital, Suzhou, Jiangsu 215200, People’s Republic of China; 2Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiuyan Yang; Guojie Zhai Email email@example.com; firstname.lastname@example.org
Background and Aims: Decreased serum retinoic acid (RA) levels have been shown to be linked with increased mortality in cardiovascular diseases. This study aimed to investigate the relationship between serum RA and 3-month functional outcome after ischemic stroke.
Methods: Between January 2019 and September 2019, we prospectively recruited ischemic stroke patients within 24 hrs of symptom onset. Serum RA levels were measured for all patients at admission. The primary outcome was defined as poor functional outcome (modified Rankin Scale 3– 6) at 90 days. The secondary outcome was defined as early neurological deterioration (END), which is considered as an increase of ≥ 1 point in motor power or total National Institutes of Health Stroke Scale score of ≥ 2 points within 7 days.
Results: A total of 217 patients were included in the analysis. The median RA levels were 2.9 ng/mL. Ninety-four (43.3%) and 65 (30.0%) patients experienced 3-month poor outcome and END, respectively. After adjusted for potential confounders, decreased levels of serum RA were associated with a higher risk of poor outcome (P for trend = 0.001) and END (P for trend = 0.002). Adding RA quartile to the existing risk factors improved risk prediction for poor outcome [net reclassification improvement (NRI) = 42.6%, P = 0.001; integrated discrimination improvement (IDI) = 5.7%, P = 0.001] and END (NRI index = 45.4%, P = 0.001; IDI = 4.3%; P = 0.005).
Conclusion: Low serum RA levels at baseline were associated with poor prognosis at 90 days after ischemic stroke, suggesting that RA may be a potential prognostic biomarker for ischemic stroke.
Keywords: acute ischemic stroke, retinoic acid, early neurological deterioration, functional outcome
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]